In the study, mice with Type 1 diabetes were infused with pre-treated blood stem cells to produce more of a protein called PD-L1, which has a potent anti-inflammatory effect against Type 1 diabetes.
The treated stem cell could curb the autoimmune reaction of the cells and reverse the abnormally high blood glucose condition in mice.
Almost all the mice were cured of diabetes in the short term, while one third maintained normal blood sugar levels for the duration of their lives, the researchers said.
"Blood stem cells have immune-regulatory abilities, but it appears that in mice and humans with diabetes, these abilities are impaired.
"We found that in diabetes, blood stem cells are defective, promoting inflammation and possibly leading to the onset of disease," Fiorina said.
The study, published in the journal Science Translational Medicine, found that the production of PD-L1 is altered in blood stem cells from diabetic mice and humans. This prevents production of PD-L1, even early in the disease.
Removing the deficiency of PD-L1, using cell-based therapy - that is low on adverse effects, because it uses the patients' own cells - may provide a novel therapeutic tool for the disease, the researchers said.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
